Filing Flows › Comparisons › CNTB vs TRAW
Connect Biopharma Holdings vs Traws Pharma: CNTB and TRAW compared
Connect Biopharma Holdings is the larger company: $2.8M of revenue in its latest quarter (Q2 2026) against $2.7M for Traws Pharma (Q2 2025). Connect Biopharma Holdings is growing faster (58× against 48× a year earlier). Traws Pharma is more profitable, with an operating margin of -45.7% against -636.0%.
Where the money goes: CNTB and TRAW
Connect Biopharma Holdings (CNTB) · Q2 2026
Connect Biopharma Holdings, Q2 2026: revenue $2.8M (58× year over year), operating margin -636.0%, net loss $17.3M, operating cash flow −$15.9M. The chart follows the revenue to costs, profit and cash.
Traws Pharma (TRAW) · Q2 2025
Traws Pharma, Q2 2025: revenue $2.7M (48× year over year), operating margin -45.7%, net loss $915K, operating cash flow −$6.0M. The chart follows the revenue to costs, profit and cash.
| Connect Biopharma Holdings (CNTB) | Traws Pharma (TRAW) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2025 |
| Revenue | $2.8M | $2.7M |
| Revenue growth, Y/Y | 58× | 48× |
| Operating margin | -636.0% | -45.7% |
| Net earnings | −$17.3M | −$915K |
| Net margin | -624.4% | -33.5% |
| Operating cash flow | −$15.9M | −$6.0M |
Questions
Which is bigger, Connect Biopharma Holdings or Traws Pharma?
Connect Biopharma Holdings is the larger company: $2.8M of revenue in its latest quarter (Q2 2026) against $2.7M for Traws Pharma (Q2 2025).
Is Connect Biopharma Holdings or Traws Pharma growing faster?
Connect Biopharma Holdings is growing faster (58× against 48× a year earlier).
Which is more profitable, Connect Biopharma Holdings or Traws Pharma?
Traws Pharma is more profitable, with an operating margin of -45.7% against -636.0%.
More: Connect Biopharma Holdings earnings · how Connect Biopharma Holdings makes money · Traws Pharma earnings · how Traws Pharma makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 12, 2026; 10-Q filed Aug 14, 2025). Fiscal quarters can end on different dates. Not investment advice.